Whitfield Assists Impact Therapeutics on its Hong Kong IPO

Press Release   ·   13 May 2026

Overview

Impact Therapeutics listed in Hong Kong on May 13, 2026, under code 7630, with reported proceeds near HK$844 million before additional allotments.

Offering terms

The biotech company offered 41,977,000 H-shares at HK$20.10 each. The source describes strong demand in both the retail and institutional tranches.

Sponsor representation

Goldman Sachs Asia and CICC Hong Kong Securities were identified as joint sponsors, the parties represented in the announcement.

Scientific focus

Impact develops cancer treatments based on synthetic lethality. Mengyu Lu, George Zheng and Qingyu Wu are among the capital markets advisers credited for the flotation.